COVID-19 sonrası devam eden semptomlar, interstisyel akciğer hastalığı oluşumu ve takip süreci
Yükleniyor...
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aralık 2019’da Çin’in Wuhan eyaletinden severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)’ye bağlı ciddi akut solunum hastalıkları bildirildi. Koronavirüs hastalığı- 2019 (COVID-19) ilişkili semptomlar hafif üst solunum yolu infeksiyonundan akut solunum sıkıntısı sendromu (ARDS)’na kadar çeşitli klinik farklılık gösterir. Taburculuk sonrası bazı hastalarda semptomların ve radyolojik bulguların devam ettiği görülmüştür. Hipertansiyon ve diyabet gibi komorbiditeler, erkek cinsiyet ve ileri yaş gibi risk faktörleri ciddi COVID-19 ve idiopatik pulmoner fibrosis (İPF) için ortak risk faktörleridir. Bununla birlikte, SARS-CoV-2 infeksiyonuna yakalanan İPF hastalarında, antifibrotik tedavinin rolü ve bunların devamı veya kesilmesi için bilimsel mantık tam olarak tanımlanmamıştır. COVID-19 pandemisinden edinilen veriler ile şiddetli akut solunum sendromu (SARS) ve Ortadoğu solunum sendromu (MERS) gibi önceki koronavirüs infeksiyonlarından elde edilen veriler, SARS-CoV-2 infeksiyonunu takiben önemli fibrotik değişiklikler olabileceğini düşündürmektedir. Bu makalede, COVID-19 pnömonisi sonrası devam eden semptomların sıklığı ve ortaya çıkabilecek interstisyel akciğer hastalığı sıklığından söz edildi. Ayrıca başta pulmoner fibrosis olmak üzere akciğerde meydana gelen interstisyel değişikliklerin önlenmesi ve solunum fonksiyonlarında azalma literatür ışığında tartışılmıştır.
n December 2019, severe acute respiratory diseases due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were reported from Wuhan province of China. The symptoms associated with Coronavirus Disease-2019 (COVID-19) range from mild upper respiratory tract infection to acute respiratory distress syndrome (ARDS). It was observed that symptoms and radiological findings continued in some patients after discharge. Comorbidities such as hypertension and diabetes, risk factors such as male gender and advanced age are common risk factors for severe COVID-19 and idiopathic pulmonary fibrosis (IPF). However, the role of anti fibrotictherapy and the scientific rationale for their continuation or discontinuation in IPF patients infected with SARS-CoV-2 have not been fully defined. Data from the COVID-19 pandemic and previous coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) suggest that there may be significant fibrotic changes following SARS-CoV-2 infection. In this article, the frequency of on going symptoms after COVID-19 pneumonia and the frequency of interstitial lung disease that may ocur were discussed. Inaddition, the prevention of interstitial changes in the lung, especially pulmonary fibrosis, and the decrease in respiratory functions are discussed in the light of the literature.
n December 2019, severe acute respiratory diseases due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were reported from Wuhan province of China. The symptoms associated with Coronavirus Disease-2019 (COVID-19) range from mild upper respiratory tract infection to acute respiratory distress syndrome (ARDS). It was observed that symptoms and radiological findings continued in some patients after discharge. Comorbidities such as hypertension and diabetes, risk factors such as male gender and advanced age are common risk factors for severe COVID-19 and idiopathic pulmonary fibrosis (IPF). However, the role of anti fibrotictherapy and the scientific rationale for their continuation or discontinuation in IPF patients infected with SARS-CoV-2 have not been fully defined. Data from the COVID-19 pandemic and previous coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) suggest that there may be significant fibrotic changes following SARS-CoV-2 infection. In this article, the frequency of on going symptoms after COVID-19 pneumonia and the frequency of interstitial lung disease that may ocur were discussed. Inaddition, the prevention of interstitial changes in the lung, especially pulmonary fibrosis, and the decrease in respiratory functions are discussed in the light of the literature.
